The biomedicine and health sector is in a good place right now, as we explain on the page about Catalonia on this website, as it already has an innovative ecosystem, with solid projects and global recognition. Nevertheless, biotech companies need new funding to see results from their research and license candidates to the pharmaceutical industry to manufacture drugs and for these to reach patients. Now is when the return on investment gets interesting.
Foreign investment in Catalonia rose 35% in 2014. According to consultancy firm EY, Barcelona is one of the top 10 most attractive cities in Europe for investing and the European capital with the most jobs created from foreign investment.
Apart from private funding, Catalonia will receive investment of 868.4 million euros through 2020 from the European Regional Development Fund (ERDF), including the Smart Specialisation Strategy RIS3CAT, which is 68.1% more than the amount received under the 7th Framework Programme (2007-2013).
28 February 2018
ProteoDesign, a biotech spin-out from Princeton University and University of Barcelona and member of CataloniaBio & HealthTech, has raised a financing round of 1.7 million euros led by existing investor Caixa Capital Risc and joined by an undisclosed private investor.
The company is developing personalized immunological treatments against cancer through patented technology discovered after more than 20 years of pioneering research in this field. The funds obtained will be used to advance candidates for drugs in the preclinical phase.
Dr. Miquel Vila Perelló, CEO of ProteoDesign, explained in this interview by CataloniaBio & HealthTech that "the conjugated antibodies are ...
24 December 2017
Devicare has signed a participative loan worth €2 million from the Innova Global line by Avançsa, assigned to the Business and Expertise Department, with the option to convert the investment into Series A stock in the mid-term.
With this new economic injection, Devicare will continue the strategic development plan of new medical solutions under the Remote Patient Monitoring concept, which simply and economically places patients at the centre of their own healthcare management, known as patient empowerment, as well as the corresponding clinical studies and trials for the expansion throughout the European and North American markets. Currently, the company has ...
19 December 2017
Cebiotex, a CataloniaBio member, has launched a new crowdequity campaign to raise €650,000 through CapitalCell in order to ensure its first drug, CEB-01 for post-op treatment of soft-tissue sarcomas, reaches paediatric oncology.
The campaign is part of a €1.6-million round of funding. The biotech firm hopes this capital will be covered with public and private funds, allowing it to begin phase I/II clinical trials on candidate CEB-01 with 15 patients in 2018, and begin proof-of concept testing for new oncology treatments for pancreatic cancer, liver cancer and brain tumours. “The first licences are expected from 2021, with ...
15 December 2017
Report of the last Lessons Learned
The biopharmaceutical industry (biopharma) is increasingly interested in acquiring medical technology (medtech) to provide innovative, effective solutions to the main global diseases. The line between these two areas has become blurred and is taking us towards a new business model. Four Catalan companies that are deeply involved in this spoke at the latest Lessons Learned session organized by CataloniaBio and Biocat with collaboration from the Health Tech Cluster, on 29 November at the Barcelona Science Park (PCB).
CataloniaBio Secretary General Melqui Calzado opened the debate looking at patient care that “requires ...
13 December 2017
Laboratorios Leti, a CataloniaBio member, has signed an agreement with the multinational MSD Animal Health to distribute its canine leishmaniasis vaccine LetiFend® in France, Italy, Greece and the United Kingdom. Leti will continue to manage the Spanish and Portuguese markets directly.
LetiFend® is the first recombinant vaccine available in Europe to prevent canine leishmaniasis, a global zoonosis caused by Leishmania infantum, which is potentially deadly and prevalent in more than 80 countries around the world. Moreover, there are few treatment possibilities, which highlights the importance of vaccination to strengthen the immune system before infection.
According to Laboratorios Leti President Jaime ...
24 November 2017
Genesis Biomed, a CataloniaBio member, was presented yesterday Genesis Ventures, a new investment fund located in Barcelona
6 November 2017
Specifically, the biotechnology firm raised 110% of its initial goal of €550,000 and has become one of the first companies in Spain to raise over half a million euros through this type of campaign.
The investment will go towards boosting the company’s industrial growth and research lines, as well as helping prepare the company to go public next year.
Vytrus has distribution deals in more than ...
11 October 2017
Catalan biomedical companies were able to attract €153.1 million in investment in 2016, a record figure for the sector. This is the main takeaway from the first Study on investment in the Biomedical industry in Catalonia 2017: Achievements and future challenges presented today by CataloniaBio and EY at the Cercle d'Economia in Barcelona before some seventy members of the association, entrepreneurs, investors and other professionals. The study, compiled with an ad-hoc methodology developed by EY, aims to paint an accurate picture of the investment landscape in Catalonia in order to measure and compare it in the coming years ...
14 September 2017
Alta Life Sciences has led a series-A round of funding for Peptomyc, which has secured €4.2 million. This was the first investment by the new life sciences fund led by Guy Paul Nohra in Barcelona, with partner Montserrat Vendrell (we recommend the video-interview from CataloniaBio) representing the fund on the Peptomyc board.
Peptomyc is a biopharmaceutical company based in Barcelona that was founded by scientists Laura Soucek and Marie-Eve Beaulieu of the Vall d'Hebron Institute ...
3 September 2017
Vytrus Biotech, a member company of CataloniaBio, has opened a round of 550,000 euros on the Capital Cell platform, where InKemia IUCT is the main investor. The crowdfunding campaign ends on 31 October and, to date, the biotechnology company has already obtained 75% of the investment.
Vytrus Biotech is a spin-off of the University of Barcelona and specialises in plant stem cells. In 2014 the company launched its first product on the dermo-cosmetic market and it currently has six of its own products. It has distribution agreements with 50 countries and one of its products has been awarded by ...